Ardelyx, Inc.
ARDXHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArdelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. With a market capitalization of $795.2M, it sits in small-cap territory. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis.
Market Cap
$795.2M
Beta
0.68
P/E (TTM)
—
P/E (Fwd)
10.60
EPS (TTM)
$-0.23
EPS (Fwd)
$0.29
ROE
-38.6%
ROA
-4.3%
Cash
$281.8M
Total Debt
$282.5M
Free CF
$20.5M
52W Change
-39.6%
Annual Financials
Cash vs Debt
Where ARDX stands vs its 150-day and 200-day moving averages
As of the October 15, 2026 close, ARDX finished 37.33% below its 150-day moving average ($5.09) and 42.31% below its 200-day moving average ($5.53). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ARDX overbought or oversold?
At the October 15, 2026 close, ARDX's RSI(14) was 28.3, in oversold territory (below 30). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ardelyx, Inc. carries $282.5M in total debt against $281.8M in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $20.5M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -38.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $52.2M (2022) to $407.3M (2025), reflecting a 681% increase over the period.
With a beta below 0.7, Ardelyx, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Ardelyx, Inc. and its sector.